Neuraminidase Inhibitors Drug Market Size & Share, by Drug Type (Oseltamivir, Zanamivir, Peramivir, Laninamivir); Route of Administration (Parenteral, Nasal, Oral); Distribution Channel (Pharmacies, Drug Stores, Retail Stores) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2028

  • Report ID: 2563
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT


Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme. The drug is used as an antiviral as the drug blocks the function of viral neuraminidases of the influenza virus. The virus is blocked by restricting its reproduction process.

The several symptoms of influenza are running nose, cough, fever, headache, fatigue, and others. The neuraminidase drug is suggested after 48 hours of appearance of the symptoms. The drug is required to be consumed in a good quantity since the development of resistance by the drug is rare.

Market Size And Forecast

The neuraminidase inhibitors drug market is anticipated to grow as a significant CAGR during the forecast period, i.e., 2020-2028. This growth can be witnessed as a result of an increasing prevalence of influenza globally. Further, the advancement in the market and development of the drug is being focused upon by the companies. This will boost the market as well. The neuraminidase inhibitors drug market is segmented by drug type, by route of administration, by distribution channel, and by region. On the basis of route of administration, the market is segmented into parenteral, nasal and oral. Under the route of administration segment, the oral sub- segment is anticipated to hold maximum share as people prefer the intake of the drug for treatment.


Growth Drivers

Increasing Awareness Among People

The government initiatives are increasing awareness among people with respect to influenza. This has enhanced the knowledge of people about the medicines and treatments that are available in the market for influenza. The market is anticipated to grow as awareness is increasing further among people. 

Rare Resistance Development

As the drug develops rare resistance to influenza, it has to be used in good quantity to achieve better results. Theprocess of resistance development is crucial to treat influenza. This is predicted to increase the demand for the drug resulting in an increase in the market growth as well.

Improving Infrastructure and Research Facilities

Development of infrastructural facilities as well as research and development is estimated to drive the market growth of the drug. Several tests are conducted before a drug is used in treatments hence, excellent devices and facilities are required to complement the research and to achieve accurate results. 


There is a lot of scope for the development in the field as drugs are being constantly improved with the help of technology and innovation. Companies are focusing on upgrading the drug and this presents an opportunity for the market to grow. Further, improving treatment, better equipment for disease detection, and hospital facilities are anticipated to increase the market demand.


The neuraminidase inhibitors drug market may experience restriction in the growth since there are side effects of the drugs, for instance, vomiting, nausea, pain, and several others. This is predicted to result in a decrease in the demand for the drug and the growth of the market. Moreover, there still prevails lack of awareness among various regions and people are unaware of the disease as well as its cure.

Market Segmentation

Our in-depth analysis of the neuraminidase inhibitors drugmarket includes the following segments:

By Drug Type

  • Oseltamivir
  • Zanamivir
  • Peramivir
  • Laninamivir

By Route Of Administration

  • Parenteral
  • Nasal
  • Oral

By Distribution Channel

  • Pharmacies
  • Drug Stores
  • Retail Stores
  • Others

By Region

On the basis of region-wise analysis, the neuraminidase inhibitors drug market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America is anticipated to dominate the market share since the research and development facilities in the region is excellent. The region is highly developed since the technological advancement is rapid along with good infrastructure. This boosts the market growth as demand is estimated to rise. The market in the Asia pacific region is anticipated to grow as a result of rising cases of influenza in the region and the development is under process. Further, people are becoming aware of the disease and its treatment.

The neuraminidase inhibitors drug market is further classified on the basis of region as mentioned below:

•  North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis

•  Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis

• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis

•  Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis

• The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating In The Market

  • F. Hoffmann La Roche
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • GlaxoSmithKline plc
  • Gilead Sciences
  • Daiichi Sankyo
  • BioCryst Ltd.


In the News

  • 17 April, 2020:F. Hoffmann La Roche developed serology test for the detection of presence of COVID- 19 in humans who have been exposed to the disease. Antibody testing is crucial for testing people who do not show any symptoms of the disease.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 2563
  • Published Date: Feb 03, 2023
  • Report Format: PDF, PPT

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying